Endocrinology

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

Retrieved on: 
Thursday, March 7, 2024

AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), today announced financial results for the year ended December 31, 2023 and provided an update on clinical and regulatory activity.

Key Points: 
  • We expect to be in position to initiate this registrational trial in the fourth quarter, pending positive feedback from the FDA.
  • Financial Results for the Year Ended December 31, 2023
    Cash Position – Lumos Pharma ended the year on December 31, 2023, with cash, cash equivalents, and short-term investments totaling $36.1 million compared to $67.4 million on December 31, 2022.
  • Cash on hand as of December 31, 2023, is expected to support operations through the third quarter of 2024.
  • ET today to discuss its financial results and to give an update on clinical programs.

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Retrieved on: 
Wednesday, March 6, 2024

SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Chair of the Board of Directors.

Key Points: 
  • Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Chair of the Board of Directors.
  • Lo.
  • Lo was most recently with Valitor, Inc., a private biotech company, serving as its Chief Executive Officer and a member of the board of directors since 2022.
  • Lo was the President, Chief Executive Officer, and member of the board of directors of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company.

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024

Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.

Key Points: 
  • Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.
  • Entitled “Unlocking the potential of insulin pumps for personalized T2D care,” the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D).
  • The six embecta-sponsored abstracts set for presentation as scientific posters, include robust data about insulin therapy via both pumps and multiple daily injections (MDI).
  • Another poster highlights data showing that in individuals with type 2 diabetes, insulin pump therapy eases constraints imposed by diabetes management and improves quality of life.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ET Today
    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • We also expect full results from our Phase 2 study in carcinoid syndrome in the first half of this year.
  • In December 2023, Crinetics reported an initial analysis of data from a subset of 27 patients.
  • Earlier today, February 28, 2024, Crinetics announced a private placement equity financing for gross proceeds of approximately $350 million.

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Retrieved on: 
Wednesday, March 6, 2024

Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies.

Key Points: 
  • Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies.
  • “The Orphan Drug Designation by the FDA highlights CELZ-101's potential to meet a significant unmet need in the prevention of allograft rejection during pancreatic islet cell transplantation which was recently approved by the FDA.
  • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is dedicated to progressing CELZ-101 through the necessary regulatory pathways, with the goal of transforming the therapeutic landscape for patients in need of islet transplantation.
  • This achievement underscores the company's dedication to leveraging the natural regenerative capabilities of the human body to create lasting health solutions.

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

Retrieved on: 
Tuesday, March 5, 2024

To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.

Key Points: 
  • To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.
  • View the full release here: https://www.businesswire.com/news/home/20240305266724/en/
    Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes.
  • The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes.
  • This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Clinical Chemistry Analyzers Market, Size, Global Forecast Report 2024-2030 Featuring Thermo Fisher Scientific, Abbott Laboratories, Siemens, Danaher, Johnson & Johnson, Sysmex ADR, HORIBA, Hitachi - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024

The "Clinical Chemistry Analyzers Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Chemistry Analyzers Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Technological improvements in clinical chemistry analyzers have enabled broader testing skills and early sickness detection, particularly in specialized sectors like cancer, gynecology, and endocrinology.
  • These essential chemical substances enable clinical chemistry analyzers to detect and measure various biomarkers, making them indispensable in the healthcare industry.
  • U.S.-based manufacturers continually introduce state-of-the-art clinical chemistry analyzers that cater to the evolving requirements of healthcare providers.

Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech

Retrieved on: 
Wednesday, February 28, 2024

Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.

Key Points: 
  • Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.
  • Starting this year, the program will focus on the femtech sector and will feature a new format.
  • The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.
  • The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16.

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • “We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses,” said Marc Stapley, Veracyte’s chief executive officer.
  • Total revenue for the fourth quarter of 2023 was $98.2 million, an increase of 22% compared to $80.3 million reported in the fourth quarter of 2022.
  • Total gross margin for the fourth quarter of 2023, including the amortization of acquired intangible assets, was 66%, compared to 61% in the fourth quarter of 2022.